OCUL earnings: real EPS beat/miss history, analyst consensus Buy, P/E -5.88. Updated 2026-07-23.
Ocular Therapeutix (OCUL) Research Hub
Ocular Therapeutix (OCUL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 10.49 USD (-8.54%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.88, market cap 1.90B. This hub links to the full technical, earnings and options research available for OCUL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 10.49 USD (-8.54%) |
| 52-week range | 8.15 USD – 11.74 USD |
| Trend regime | Range |
| 14-day RSI | 60.8 (Bullish) |
| Trailing P/E | -5.88 |
| Market cap | 1.90B |
| Dividend yield | 0.00% |
Available research for OCUL
Covered Call on OCUL: how it works, illustrative setup around the real 10.49 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on OCUL: how it works, illustrative setup around the real 10.49 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on OCUL: how it works, illustrative setup around the real 10.49 USD price, max profit/loss, breakeven and when to use it. Educational.
OCUL technical analysis: range, last 10.49 USD, RSI 60.8, 52w range 8.15 USD–11.74 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is OCUL in?
Ocular Therapeutix (OCUL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is OCUL in an uptrend or downtrend?
As of 2026-09-11, OCUL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is OCUL's trailing P/E ratio?
OCUL's trailing P/E is -5.88, with a market cap of 1.90B. See the earnings research page for full valuation detail.